查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128096

CRISPR市場規模、佔有率、成長、全球產業分析、區域趨勢以及2026年至2034年的預測。

CRISPR Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

CRISPR市場成長要素

全球CRISPR市場預計在2025年達到30.5億美元，2026年成長至34.1億美元，並在2034年達到108.1億美元，預測期內複合年成長率高達15.49%。基因編輯技術在生物技術、藥物研發、藥物發現和治療開發等領域的快速普及，是推動市場擴張的重要因素。憑藉強大的生物技術基礎設施、充足的研究經費以及主要市場參與企業的存在，北美在2025年將以43.93%的市場佔有率引領全球CRISPR市場。

CRISPR技術已成為基因組工程領域最具創新性的工具之一，能夠實現高精度基因編輯、功能基因組學研究、細胞工程和轉化研究。在對先進基因編輯工作流程日益成長的需求以及精準醫療和罕見疾病研究投資不斷增加的推動下，市場持續加速發展。賽默飛世爾科技、丹納赫公司（IDT和Aldevron）、默克集團、金斯瑞生物科技、Syntego和寶生物等領先企業正透過投資試劑、核酸酶、生物資訊工具和治療開發平台，持續拓展其CRISPR相關產品系列。

市場趨勢

基因組編輯技術的進步和基於CRISPR療法的開發是影響CRISPR市場發展的關鍵趨勢之一。研究人員日益關注提高編輯精度、減少脫靶效應以及加速轉化為臨床應用。個人化基因編輯療法和新一代CRISPR平台的出現，為技術提供者和生技公司創造了巨大的機會。

市場促進因素

基因編輯技術在生物技術領域的應用日益廣泛

基因編輯工具在生物技術和製藥研究中的日益普及是推動CRISPR市場成長的關鍵因素。生物技術公司正擴大利用CRISPR技術進行標靶識別、功能基因組學、細胞工程和治療藥物開發。這項技術能夠縮短研究週期並提高準確性，從而推動了對引導RNA、核酸酶、遞送系統和分析服務的需求。此外，CRISPR技術在個人化醫療和罕見疾病治療領域應用範圍的不斷擴大也持續刺激著市場需求。

市場限制因素

基因編輯的倫理問題

圍繞人類基因組編輯的倫理問題仍然是市場擴張的主要限制。對生殖細胞系修飾、胚胎編輯、知情同意以及基因技術潛在濫用的擔憂，促使監管審查日益嚴格。這些挑戰可能會延緩某些應用的商業化進程，並促使參與企業面臨更嚴格的合規要求。

市場機遇

加大基因研究的投資

對基因和基因組研究投入的增加，為CRISPR市場創造了巨大的機會。來自政府、研究機構、生技公司和個人投資者的資金，正支持著先進基因組編輯技術的發展。這些投入的增加，使各機構能夠拓展研究能力，加速臨床前試驗，並將有前景的療法推進臨床開發階段。

市場挑戰

高昂的研發成本

開發基於 CRISPR 的療法需要在研究、生產、法規核准和臨床試驗方面投入大量資金。高昂的研發成本往往成為中小企業和新創公司的一大障礙，限制了能夠進入開發平臺的專案數量。維持長期資金籌措仍然是整個產業面臨的重大挑戰。

細分分析

按產品供應

預計到2025年，產品細分市場將成為市場成長的主要驅動力，這主要得益於研究和治療流程中使用的試劑盒、試劑、CRISPR文庫、核酸酶、載體和遞送工具的持續需求。基因編輯試劑的不斷創新也為此細分市場的成長提供了支持。

在預測期內，受脫靶分析、基因組數據解讀和工作流程最佳化需求不斷成長的推動，軟體和生物資訊工具領域預計將經歷最快的成長。

透過技術

預計到2025年，CRISPR-Cas9技術將佔最大的市場佔有率，這主要得益於其在基因編輯研究和治療應用領域的廣泛應用。其高效的編輯效率和廣泛的市場覆蓋範圍將繼續鞏固其市場主導地位。

由於 CRISPR-Cas13 技術在 RNA 編輯和分子診斷領域的應用不斷擴展，預計該領域將迎來強勁成長。

用途別

到2025年，基礎研究和轉化研究領域將主導市場。學術機構、研究組織和生物技術公司將廣泛利用CRISPR技術進行基因功能研究、疾病建模和訊號路徑分析。

隨著基於 CRISPR 的療法進入臨床前和臨床開發階段，治療開發領域預計將快速成長。

最終用戶

到2025年，製藥和生物技術產業將佔最大的市場佔有率。這些企業正在大力投資CRISPR技術驅動的藥物研發、基因治療和精準醫療計畫。

由於基因編輯研究和生產活動的外包程度不斷提高，CRO 和 CDMO 領域預計將顯著成長。

區域展望

北美洲

北美仍是最大的區域市場，預計到2025年將達到13.4億美元。強大的生物技術基礎設施、先進的研究能力以及對基因組醫學的大量投資正在推動該地區的成長。美國仍然是該地區收入的最大貢獻者。

歐洲

在歐洲，預計在預測期內將實現強勁成長，這得益於基因研究計畫的擴展、公私合營以及 CRISPR 技術在藥物開發和轉化醫學中日益廣泛的應用。

亞太地區

亞太地區預計將成為成長最快的區域市場。推動這一市場擴張的因素包括中國、日本、印度和韓國等國家對生物技術投資的增加、基因組研究的擴展以及醫療保健基礎設施的建設。

拉丁美洲、中東和非洲

由於對生命科學研究的投資增加、生物技術能力的提高以及對先進基因組技術的認知不斷提高，預計這些地區將經歷適度成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • CRISPR技術的進步
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 主要國家和地區的監管趨勢

第5章：2021-2034年全球CRISPR市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品/服務分類。
    • 軟體和生物資訊學工具
    • 服務
  • 市場分析、洞察與預測：按技術分類
    • CRISPR-Cas9
    • CRISPR-Cas12
    • CRISPR-Cas13
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 基礎研究與轉化研究
    • 藥物發現和標靶識別
    • 臨床前模型開發
    • 藥物研發
    • 診斷
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 製藥和生物技術公司
    • 學術研究機構
    • CRO／CDMO
    • 診斷檢查室
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美CRISPR市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲 CRISPR 市場分析、洞察與預測（2021-2034 年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區 CRISPR 市場分析、洞察與預測（2021-2034 年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲 CRISPR 市場分析、洞察與預測（2021-2034 年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲CRISPR市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Revvity Discovery Limited
    • GenScript
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation（Integrated DNA Technologies, Inc.）
    • Synthego
    • Takara Bio Inc.
    • OriGene Technologies, Inc.
    • Twist Biosciences
    • BPS Bioscience, Inc.
Product Code: FBI116099

Growth Factors of CRISPR Market

The global CRISPR market was valued at USD 3.05 billion in 2025 and is projected to grow from USD 3.41 billion in 2026 to USD 10.81 billion by 2034, registering a strong CAGR of 15.49% during the forecast period. The rapid adoption of gene-editing technologies across biotechnology, pharmaceutical research, drug discovery, and therapeutic development is significantly driving market expansion. North America dominated the global CRISPR market with a 43.93% share in 2025, supported by strong biotechnology infrastructure, extensive research funding, and the presence of leading market participants.

CRISPR technology has become one of the most transformative tools in genome engineering, enabling highly precise gene editing, functional genomics studies, cell engineering, and translational research. The increasing demand for advanced gene-editing workflows, coupled with growing investments in precision medicine and rare disease research, continues to accelerate market growth. Major companies such as Thermo Fisher Scientific, Danaher Corporation (IDT and Aldevron), Merck KGaA, GenScript, Synthego, and Takara Bio are expanding their CRISPR portfolios through investments in reagents, nucleases, bioinformatics tools, and therapeutic development platforms.

Market Trends

A major trend shaping the CRISPR market is the advancement of genome engineering technologies and the development of CRISPR-based therapies. Researchers are increasingly focusing on improving editing accuracy, reducing off-target effects, and accelerating clinical translation. The emergence of personalized gene-editing therapies and next-generation CRISPR platforms is creating significant opportunities for technology providers and biotechnology companies.

Market Drivers

Increasing Adoption of Gene Editing Technologies in Biotechnology

The growing use of gene-editing tools in biotechnology and pharmaceutical research is a key factor driving CRISPR market growth. Biotechnology companies are increasingly utilizing CRISPR for target identification, functional genomics, cell engineering, and therapeutic development. The technology's ability to accelerate research timelines and improve precision has increased demand for guide RNAs, nucleases, delivery systems, and analytical services. Furthermore, expanding applications in personalized medicine and rare disease treatment continue to strengthen market demand.

Market Restraints

Ethical Concerns Related to Gene Editing

Ethical issues surrounding human genome editing remain a significant restraint for market expansion. Concerns regarding germline modification, embryo editing, consent, and potential misuse of genetic technologies have led to increased regulatory scrutiny. These challenges may delay commercialization of certain applications and increase compliance requirements for industry participants.

Market Opportunities

Rising Investments in Genetic Research

Increasing investments in genetic and genomic research are creating substantial opportunities for the CRISPR market. Funding from governments, research institutions, biotechnology firms, and private investors is supporting the development of advanced genome-editing technologies. Higher investments are enabling organizations to expand research capabilities, accelerate preclinical studies, and move promising therapies toward clinical development.

Market Challenges

High Research and Development Costs

The development of CRISPR-based therapies requires significant investments in research, manufacturing, regulatory approvals, and clinical trials. High R&D expenses create barriers for smaller companies and startups, often limiting the number of projects that can advance through the development pipeline. Maintaining long-term funding remains a major challenge across the industry.

Segmentation Analysis

By Offering

The products segment dominated the market in 2025 due to the recurring demand for kits, reagents, CRISPR libraries, nucleases, vectors, and delivery tools used in research and therapeutic workflows. Continuous innovation in gene-editing reagents is supporting segment growth.

The software and bioinformatics tools segment is expected to witness the fastest growth during the forecast period, driven by increasing demand for off-target analysis, genomic data interpretation, and workflow optimization.

By Technology

The CRISPR-Cas9 segment held the largest market share in 2025 due to its widespread adoption in gene-editing research and therapeutic applications. Its high editing efficiency and extensive commercial availability continue to support market leadership.

The CRISPR-Cas13 segment is expected to experience strong growth owing to its emerging applications in RNA editing and molecular diagnostics.

By Application

The basic and translational research segment dominated the market in 2025. Academic institutions, research laboratories, and biotechnology companies extensively utilize CRISPR for gene function studies, disease modeling, and pathway analysis.

The therapeutic development segment is anticipated to grow rapidly as more CRISPR-based therapies enter preclinical and clinical development stages.

By End User

The pharmaceutical and biotechnology companies segment accounted for the largest market share in 2025. These organizations are making significant investments in CRISPR-based drug discovery, gene therapies, and precision medicine programs.

The CROs and CDMOs segment is projected to witness substantial growth due to increasing outsourcing of gene-editing research and manufacturing activities.

Regional Outlook

North America

North America remained the largest regional market, reaching USD 1.34 billion in 2025. Strong biotechnology infrastructure, advanced research capabilities, and substantial funding for genomic medicine support regional growth. The U.S. continues to be the leading contributor to regional revenues.

Europe

Europe is expected to experience robust growth during the forecast period, supported by expanding genetic research programs, public-private collaborations, and growing adoption of CRISPR technologies in drug development and translational medicine.

Asia Pacific

Asia Pacific is projected to be the fastest-growing regional market. Rising biotechnology investments, expanding genomics research, and improving healthcare infrastructure in countries such as China, Japan, India, and South Korea are driving market expansion.

Latin America and Middle East & Africa

These regions are witnessing gradual growth due to increasing investments in life sciences research, improving biotechnology capabilities, and rising awareness of advanced genomic technologies.

Competitive Landscape

The global CRISPR market is moderately fragmented, with leading companies focusing on product innovation, strategic collaborations, acquisitions, and expansion of translational research capabilities. Major players include Thermo Fisher Scientific Inc., Danaher Corporation (IDT and Aldevron), Merck KGaA, GenScript, Synthego, Takara Bio Inc., OriGene Technologies, Twist Bioscience, Revvity Discovery Limited, and BPS Bioscience.

Recent developments include the launch of advanced CRISPR reagents, strategic partnerships for therapeutic development, AI-enhanced gene-editing platforms, and investments in genome engineering technologies aimed at improving precision and accelerating clinical translation.

Conclusion

The CRISPR market is entering a phase of rapid expansion, driven by growing adoption of gene-editing technologies, rising investments in genetic research, and increasing development of CRISPR-based therapeutics. Valued at USD 3.05 billion in 2025, the market is expected to reach USD 10.81 billion by 2034, reflecting the transformative role of genome engineering in biotechnology and precision medicine. While ethical concerns and high development costs remain challenges, continued innovation, expanding clinical applications, and strong industry investment are expected to create significant growth opportunities throughout the forecast period.

Segmentation By Offering, Technology, Application, End User, and Region

By Offering * Products

    • Instruments
    • CRISPR Libraries
    • Enzymes/Cas Proteins/Nucleases
    • Vectors/Plasmids/Delivery Tools
    • Others
  • Software & Bioinformatics Tools
  • Services

By Technology * CRISPR-Cas9

  • CRISPR-Cas12
  • CRISPR-Cas13
  • Others

By Application * Basic & Translational Research

  • Drug Discovery & Target Identification
  • Preclinical Model Development
  • Therapeutic Development
  • Diagnostics
  • Others

By End User * Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes
  • CROs/CDMOs
  • Diagnostic Laboratories
  • Others

By Region * North America (By Offering, Technology, Application, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Offering, Technology, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Offering, Technology, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Offering, Technology, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Offering, Technology, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Technological Advancements in CRISPR Technology
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Offering
    • 5.1.1. Products
      • 5.1.1.1. Kits & Reagents
      • 5.1.1.2. CRISPR Libraries
      • 5.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 5.1.1.4. Vectors/Plasmids/Delivery Tools
      • 5.1.1.5. Others
    • 5.1.2. Software & Bioinformatics Tools
    • 5.1.3. Services
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. CRISPR-Cas9
    • 5.2.2. CRISPR-Cas12
    • 5.2.3. CRISPR-Cas13
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Basic & Translational Research
    • 5.3.2. Drug Discovery & Target Identification
    • 5.3.3. Preclinical Model Development
    • 5.3.4. Therapeutic Development
    • 5.3.5. Diagnostics
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Pharmaceutical & Biotechnology Companies
    • 5.4.2. Academic & Research Institutes
    • 5.4.3. CROs/CDMOs
    • 5.4.4. Diagnostic Laboratories
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Offering
    • 6.1.1. Products
      • 6.1.1.1. Kits & Reagents
      • 6.1.1.2. CRISPR Libraries
      • 6.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 6.1.1.4. Vectors/Plasmids/Delivery Tools
      • 6.1.1.5. Others
    • 6.1.2. Software & Bioinformatics Tools
    • 6.1.3. Services
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. CRISPR-Cas9
    • 6.2.2. CRISPR-Cas12
    • 6.2.3. CRISPR-Cas13
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Basic & Translational Research
    • 6.3.2. Drug Discovery & Target Identification
    • 6.3.3. Preclinical Model Development
    • 6.3.4. Therapeutic Development
    • 6.3.5. Diagnostics
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Pharmaceutical & Biotechnology Companies
    • 6.4.2. Academic & Research Institutes
    • 6.4.3. CROs/CDMOs
    • 6.4.4. Diagnostic Laboratories
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Offering
    • 7.1.1. Products
      • 7.1.1.1. Kits & Reagents
      • 7.1.1.2. CRISPR Libraries
      • 7.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 7.1.1.4. Vectors/Plasmids/Delivery Tools
      • 7.1.1.5. Others
    • 7.1.2. Software & Bioinformatics Tools
    • 7.1.3. Services
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. CRISPR-Cas9
    • 7.2.2. CRISPR-Cas12
    • 7.2.3. CRISPR-Cas13
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Basic & Translational Research
    • 7.3.2. Drug Discovery & Target Identification
    • 7.3.3. Preclinical Model Development
    • 7.3.4. Therapeutic Development
    • 7.3.5. Diagnostics
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Pharmaceutical & Biotechnology Companies
    • 7.4.2. Academic & Research Institutes
    • 7.4.3. CROs/CDMOs
    • 7.4.4. Diagnostic Laboratories
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Offering
    • 8.1.1. Products
      • 8.1.1.1. Kits & Reagents
      • 8.1.1.2. CRISPR Libraries
      • 8.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 8.1.1.4. Vectors/Plasmids/Delivery Tools
      • 8.1.1.5. Others
    • 8.1.2. Software & Bioinformatics Tools
    • 8.1.3. Services
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. CRISPR-Cas9
    • 8.2.2. CRISPR-Cas12
    • 8.2.3. CRISPR-Cas13
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Basic & Translational Research
    • 8.3.2. Drug Discovery & Target Identification
    • 8.3.3. Preclinical Model Development
    • 8.3.4. Therapeutic Development
    • 8.3.5. Diagnostics
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Pharmaceutical & Biotechnology Companies
    • 8.4.2. Academic & Research Institutes
    • 8.4.3. CROs/CDMOs
    • 8.4.4. Diagnostic Laboratories
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Offering
    • 9.1.1. Products
      • 9.1.1.1. Kits & Reagents
      • 9.1.1.2. CRISPR Libraries
      • 9.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 9.1.1.4. Vectors/Plasmids/Delivery Tools
      • 9.1.1.5. Others
    • 9.1.2. Software & Bioinformatics Tools
    • 9.1.3. Services
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. CRISPR-Cas9
    • 9.2.2. CRISPR-Cas12
    • 9.2.3. CRISPR-Cas13
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Basic & Translational Research
    • 9.3.2. Drug Discovery & Target Identification
    • 9.3.3. Preclinical Model Development
    • 9.3.4. Therapeutic Development
    • 9.3.5. Diagnostics
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Pharmaceutical & Biotechnology Companies
    • 9.4.2. Academic & Research Institutes
    • 9.4.3. CROs/CDMOs
    • 9.4.4. Diagnostic Laboratories
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa CRISPR Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Offering
    • 10.1.1. Products
      • 10.1.1.1. Kits & Reagents
      • 10.1.1.2. CRISPR Libraries
      • 10.1.1.3. Enzymes/Cas Proteins/Nucleases
      • 10.1.1.4. Vectors/Plasmids/Delivery Tools
      • 10.1.1.5. Others
    • 10.1.2. Software & Bioinformatics Tools
    • 10.1.3. Services
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. CRISPR-Cas9
    • 10.2.2. CRISPR-Cas12
    • 10.2.3. CRISPR-Cas13
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Application
    • 10.3.1. Basic & Translational Research
    • 10.3.2. Drug Discovery & Target Identification
    • 10.3.3. Preclinical Model Development
    • 10.3.4. Therapeutic Development
    • 10.3.5. Diagnostics
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Pharmaceutical & Biotechnology Companies
    • 10.4.2. Academic & Research Institutes
    • 10.4.3. CROs/CDMOs
    • 10.4.4. Diagnostic Laboratories
    • 10.4.5. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Revvity Discovery Limited
    • 11.2.2. GenScript
    • 11.2.3. Merck KGaA
    • 11.2.4. Thermo Fisher Scientific Inc.
    • 11.2.5. Danaher Corporation (Integrated DNA Technologies, Inc.)
    • 11.2.6. Synthego
    • 11.2.7. Takara Bio Inc.
    • 11.2.8. OriGene Technologies, Inc.
    • 11.2.9. Twist Biosciences
    • 11.2.10. BPS Bioscience, Inc.

List of Tables

  • Table 1: Global CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 2: Global CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 3: Global CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 4: Global CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 5: Global CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 6: Global CRISPR Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 7: North America CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 8: North America CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 9: North America CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 10: North America CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: North America CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 12: North America CRISPR Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 14: Europe CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 15: Europe CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 16: Europe CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 17: Europe CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 18: Europe CRISPR Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 20: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 21: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 22: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 24: Asia Pacific CRISPR Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 26: Latin America CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 27: Latin America CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 28: Latin America CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 29: Latin America CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 30: Latin America CRISPR Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, By Offering, 2021-2034
  • Table 32: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 33: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 34: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 35: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, By End User, 2021-2034
  • Table 36: Middle East & Africa CRISPR Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global CRISPR Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global CRISPR Market Value Share (%), By Offering, 2025 & 2034
  • Figure 3: Global CRISPR Market Value Share (%), By Technology, 2025 & 2034
  • Figure 4: Global CRISPR Market Value Share (%), By Application, 2025 & 2034
  • Figure 5: Global CRISPR Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global CRISPR Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America CRISPR Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 8: North America CRISPR Market Value Share (%), By Offering, 2025
  • Figure 9: North America CRISPR Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 10: North America CRISPR Market Value Share (%), By Technology, 2025
  • Figure 11: North America CRISPR Market Value (USD billion), By Application, 2025 & 2034
  • Figure 12: North America CRISPR Market Value Share (%), By Application, 2025
  • Figure 13: North America CRISPR Market Value (USD billion), By End User, 2025 & 2034
  • Figure 14: North America CRISPR Market Value Share (%), By End User, 2025
  • Figure 15: North America CRISPR Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America CRISPR Market Value Share (%), by Country, 2025
  • Figure 17: Europe CRISPR Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 18: Europe CRISPR Market Value Share (%), By Offering, 2025
  • Figure 19: Europe CRISPR Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 20: Europe CRISPR Market Value Share (%), By Technology, 2025
  • Figure 21: Europe CRISPR Market Value (USD billion), By Application, 2025 & 2034
  • Figure 22: Europe CRISPR Market Value Share (%), By Application, 2025
  • Figure 23: Europe CRISPR Market Value (USD billion), By End User, 2025 & 2034
  • Figure 24: Europe CRISPR Market Value Share (%), By End User, 2025
  • Figure 25: Europe CRISPR Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe CRISPR Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 27: Asia Pacific CRISPR Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 28: Asia Pacific CRISPR Market Value Share (%), By Offering, 2025
  • Figure 29: Asia Pacific CRISPR Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 30: Asia Pacific CRISPR Market Value Share (%), By Technology, 2025
  • Figure 31: Asia Pacific CRISPR Market Value (USD billion), By Application, 2025 & 2034
  • Figure 32: Asia Pacific CRISPR Market Value Share (%), By Application, 2025
  • Figure 33: Asia Pacific CRISPR Market Value (USD billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific CRISPR Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific CRISPR Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific CRISPR Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Latin America CRISPR Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 38: Latin America CRISPR Market Value Share (%), By Offering, 2025
  • Figure 39: Latin America CRISPR Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 40: Latin America CRISPR Market Value Share (%), By Technology, 2025
  • Figure 41: Latin America CRISPR Market Value (USD billion), By Application, 2025 & 2034
  • Figure 42: Latin America CRISPR Market Value Share (%), By Application, 2025
  • Figure 43: Latin America CRISPR Market Value (USD billion), By End User, 2025 & 2034
  • Figure 44: Latin America CRISPR Market Value Share (%), By End User, 2025
  • Figure 45: Latin America CRISPR Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America CRISPR Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa CRISPR Market Value (USD billion), By Offering, 2025 & 2034
  • Figure 48: Middle East & Africa CRISPR Market Value Share (%), By Offering, 2025
  • Figure 49: Middle East & Africa CRISPR Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 50: Middle East & Africa CRISPR Market Value Share (%), By Technology, 2025
  • Figure 51: Middle East & Africa CRISPR Market Value (USD billion), By Application, 2025 & 2034
  • Figure 52: Middle East & Africa CRISPR Market Value Share (%), By Application, 2025
  • Figure 53: Middle East & Africa CRISPR Market Value (USD billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa CRISPR Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa CRISPR Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa CRISPR Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 57: Global CRISPR Market Share (%), by Company, 2025